Scientific Reports (Nov 2024)
Effects of repeated intra-silicone oil injections of methotrexate on proliferative vitreoretinopathy grade C: a multicenter randomized controlled trial
- Ramin Nourinia,
- Sare Safi,
- Mehrad Mohammadpour,
- Hamid Riazi-Esfahani,
- Mohammad Reza Ansari Astaneh,
- Khalil Ghasemi Falavarjani,
- Alireza Ramezani,
- Saeed Karimi,
- Sahba Fekri,
- Nazanin Ebrahimiadib,
- Elias Khalili Pour,
- Homayoun Nikkhah,
- Nasser Shoeibi,
- Narges Hassanpoor,
- Maryam Hosseini,
- Mojtaba Abrishami,
- Fatemeh Abdi,
- Anoushiravan Rahimi,
- Mohammad Hossein Jabbarpoor Bonyadi,
- Siamak Moradian,
- Sina Khosravi Mirzaei,
- Hamid Safi,
- Pasha Anvari,
- Kaveh Fadakar,
- Masoud Mirghorbani,
- Niloufar Mohammadbagheri,
- Firouze Hatami,
- Bahareh Kheiri,
- Mehdi Yaseri,
- Zahra Khorrami,
- Hamid Ahmadieh
Affiliations
- Ramin Nourinia
- Ophthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences
- Sare Safi
- Ophthalmic Epidemiology Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences
- Mehrad Mohammadpour
- Ophthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences
- Hamid Riazi-Esfahani
- Translational Ophthalmology Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences
- Mohammad Reza Ansari Astaneh
- Eye Research Center, Mashhad University of Medical Sciences
- Khalil Ghasemi Falavarjani
- Eye Research Center, The five Senses Health Institute, Moheb Kowsar Hospital, School of Medicine, Iran University of Medical Sciences
- Alireza Ramezani
- Ophthalmic Epidemiology Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences
- Saeed Karimi
- Ophthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences
- Sahba Fekri
- Ophthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences
- Nazanin Ebrahimiadib
- Translational Ophthalmology Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences
- Elias Khalili Pour
- Translational Ophthalmology Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences
- Homayoun Nikkhah
- Ophthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences
- Nasser Shoeibi
- Eye Research Center, Mashhad University of Medical Sciences
- Narges Hassanpoor
- Retina & Vitreous Service, Nikookari Eye Hospital, Tabriz University of Medical Sciences
- Maryam Hosseini
- Eye Research Center, Mashhad University of Medical Sciences
- Mojtaba Abrishami
- Eye Research Center, Mashhad University of Medical Sciences
- Fatemeh Abdi
- Eye Research Center, The five Senses Health Institute, Moheb Kowsar Hospital, School of Medicine, Iran University of Medical Sciences
- Anoushiravan Rahimi
- Negah Aref Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences
- Mohammad Hossein Jabbarpoor Bonyadi
- Hakiman-e Noor Eye Hospital
- Siamak Moradian
- Ophthalmic Epidemiology Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences
- Sina Khosravi Mirzaei
- Ophthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences
- Hamid Safi
- Ophthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences
- Pasha Anvari
- Eye Research Center, The five Senses Health Institute, Moheb Kowsar Hospital, School of Medicine, Iran University of Medical Sciences
- Kaveh Fadakar
- Translational Ophthalmology Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences
- Masoud Mirghorbani
- Translational Ophthalmology Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences
- Niloufar Mohammadbagheri
- Ophthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences
- Firouze Hatami
- Ophthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences
- Bahareh Kheiri
- Ophthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences
- Mehdi Yaseri
- Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences
- Zahra Khorrami
- Ophthalmic Epidemiology Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences
- Hamid Ahmadieh
- Ophthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences
- DOI
- https://doi.org/10.1038/s41598-024-79708-1
- Journal volume & issue
-
Vol. 14,
no. 1
pp. 1 – 9
Abstract
Abstract In this randomized controlled trial, we assessed the effects of three consecutive intra-silicone oil (SO) injections of methotrexate (MTX) on the outcomes of surgery for proliferative vitreoretinopathy grade C (PVR-C). Seventy-four eyes of 74 patients with PVR-C were included. Of these, 37 eyes were assigned to the MTX group and 37 eyes to the control group. Fourteen patients failed to comply with the 6-month follow-up period. All eyes underwent vitrectomy and SO injection. In the MTX group, 250 µg MTX was injected into the SO after surgery and at weeks 3 and 6 postoperatively. The primary outcome was the retinal reattachment rate at 6 months. The secondary outcomes included limited PVR recurrence and adverse events. Retinal reattachment was achieved in 22 eyes (73.3%) in the MTX group and 23 eyes (76.7%) in the control group (difference: -3.4%, 95% CI: -25.2–18.5%). Limited PVR recurrence was observed in one eye (4.5%) in the MTX group versus nine eyes (39.1%) in the control group at 6 months (P = 0.01). No adverse effects were observed. Adjunctive treatment with three consecutive applications of intra-SO MTX did not reveal a significant effect on the retinal re-detachment rate but could statistically significantly reduce limited PVR recurrence. Trial registration: http//ClinicalTrials.gov NCT04482543, 22/07/2020.
Keywords
